BioNTech SE 2021 SR
The report highlights BioNTech's transition to a commercial-stage company in 2021, supplying 2.6 billion COVID-19 vaccine doses globally. It outlines a commitment to vaccine equity through the BioNTainer modular manufacturing solution for Africa. The company established a new climate strategy with science-based targets aligned with a 1.5°C pathway and achieved an ISS ESG Prime rating. Financial results show total revenues of 19.0 billion Euros. The report also details the company's growth to over 3,000 employees and its focus on democratizing access to novel medicines.
Company: BioNTech SE
Sector: Professional & technical services
Country: Germany
Year: 2021
Type: SR
Pages: 96
Back to company
BioNTech SE
Sustainability Report
The report highlights BioNTech's transition to a commercial-stage company in 2021, supplying 2.6 billion COVID-19 vaccine doses globally. It outlines a commitment to vaccine equity through the BioNTainer modular manufacturing solution for Africa. The company established a new climate strategy with science-based targets aligned with a 1.5°C pathway and achieved an ISS ESG Prime rating. Financial results show total revenues of 19.0 billion Euros. The report also details the company's growth to over 3,000 employees and its focus on democratizing access to novel medicines.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Apr 6, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees